Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRIT: Hetrombopag for CIT in Gynecologic Malignancies
NCT06099925Phase 2Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Oct 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of hetrombopag in chemotherapy-induced thrombocytopenia (CIT), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Efficacy of hetrombopag (Incidence of Grade II or above Chemotherapy-induced Thrombocytopenia) at 14 days. Status: unknown.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT06099925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06099925.